Sometimes, the most innovative ideas are not enough.
I have just added Vicarious Surgical to the robotic platforms section of this website. From an engineering perspective, it was one of the most original systems ever conceived. Instead of refining the traditional robotic architecture, Vicarious proposed something radically different: two fully articulated robotic arms that unfold inside the abdominal cavity after entering through a single port.
Now, reports indicate that the company’s Board of Directors has recommended liquidating the company and dissolving the business, following unsuccessful attempts to secure additional financing or find a buyer. A shareholder vote is scheduled to approve the plan, but unless something unexpected happens, this appears to be the end of the road for one of the most ambitious projects in surgical robotics.
The financial numbers tell a difficult story: dwindling cash reserves, continuing operating losses, suspension of NYSE trading earlier this year, and no successful strategic alternative despite efforts to raise capital or sell the company. This reminds us how challenging this industry really is.
Developing a surgical robot is unlike developing almost any other medical technology. The engineering is extraordinarily complex. Regulatory approval is demanding. Clinical validation takes years. Manufacturing must scale while maintaining exceptional quality. And, perhaps most importantly, hospitals are understandably reluctant to invest in platforms without long-term support, proven clinical value, and a sustainable installed base.
This naturally raises a broader question: how many soft-tissue robotic platforms can the market actually sustain? We will discuss this in the another post.
For now, I have just added a new section to the robotic platforms area of this website dedicated to robotic systems that did not make it to market. Their stories are also part of the history of surgical robotics, and many of their innovations will almost certainly influence future generations of surgical systems.
So, in the next post, I’d like to open the discussion on why some robotic companies succeed while others do not. Is it purely about technology? Is it funding? Timing? Regulation? Clinical adoption? Or …
… has the market simply become too crowded?
The debate has only just begun.
J Granell. Jul 21, 2026